STUDboardsPlay · Research · Self · Fit · Money · Learn · Study · Plan · Token STUDtokenOptional

STUDresearch · Non-peptide

5-Amino-1MQ

Also known as

5-amino-1-methylquinolinium · 5-amino-1-methylquinolinium iodide · 5-amino-1-methylquinolinium monochloride · 5A1MQ · 5A-1MQ · 5A-M1Q · 5A-1MQ (monochloride salt) · 5-AMQ · 5-AMQ (PK literature) · 5-Amino-1-MQ · 5 amino 1MQ · NNMT inhibitor 5-amino-1MQ · NNMTi 5-amino-1MQ · NNMTi 5A-1MQ

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗
Non-peptide Lots of talk Systemic Oral / SubQ Metabolic research compounds

Systemic — NNMT / NAD+ and fat-metabolism discussion; adipose, muscle and liver exposure comes from animal work, not spot-fat targeting.

What people say 5-Amino-1MQ is a small-molecule NNMT inhibitor discussed for fat loss, recomp and GLP-1 plateaus—not a peptide, GLP-1 or proven human fat-loss treatment. Doses people talk about
Community oral band50–150 mg/day oral

Often 50 mg capsules; once-daily, split and one-to-three-times-daily descriptions coexist. Lower and higher chart variants remain in the full notes.

Community injectable mg charts2.5–5 mg/day SC; other charts 10–30 mg/day

The 5 mg total appears once daily or as 2.5 mg twice daily. These are separate from the mcg tables.

Community injectable mcg charts150–600 mcg/day SC

Reported 12-week tables, sometimes AM/PM splits—not a validated ladder or an oral equivalent.

These amounts describe the existing discussion, not an endorsed progression. Rat bioavailability cannot convert oral amounts to human SC amounts.

Half-life & effect duration

Half-life in the body
  • Oral · ratsAbout 6.9 hours
  • IV · ratsAbout 3.8 hours
Felt duration people report
  • Early effectsOften subtle; energy reports vary
  • Continued oral useChanges after 2–3 weeks in one log; no change after 30 days in another
  • MoodMuted affect around week 3 in one account
Timing context & sources
How it may feel Reports range from little or nothing to subtle alertness, warmth or easier waist progress over weeks. GI upset, early fatigue, sleep disruption and muted mood also appear; diet and multi-agent stacks make attribution weak.
Cycles people discuss The existing charts describe 8–12-week blocks, shorter 4–6-week experiments and varied breaks—2–4, 4–6 or 4–8 weeks. Others use it through a cut; these are community habits, not validated washout or long-term safety schedules. Timing Morning or earlier-day oral use is common in the notes, with fasted and food-for-GI approaches. Once-daily and AM/midday splits both appear; rat half-life does not validate a human interval. Stacks GLP-1s, MOTS-c and NAD-related products recur in recomp discussion. The reviewed experiences include co-use and null reports; a stack is not evidence that 5-Amino-1MQ caused the change. Watch for Source quality: Mislabeling enzyme vs inhibitor, wrong dose unit (mg vs mcg), weak or fake COAs, salt-form ambiguity.
Related
SemaglutideTirzepatideRetatrutideMOTS-cNMN

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

About 6.9 h after oral dosing in rats; the IV mean was about 3.8 h.

The study reported oral 6.90 ± 1.20 h and IV 3.80 ± 1.10 h, with 38.4% oral bioavailability.

Not measured human capsule or SC kinetics. Different routes/species and unresolved salt form prevent a human dose conversion.

Felt duration people report

No dependable single-dose benefit duration emerges from the inspected reports.

One oral month-log describes subtle changes after 2–3 weeks and muted affect around week 3; another user reports nothing after 30 days. SC reports range from limited energy to positive co-use impressions or no effect.

These are conflicting self-reports, not PK. Product identity, dose, route, diet and stacks differ; multi-week impressions are not hours of drug action.

  • Experience with 5-Amino-1MQ after a month (opens in a new tab)Actual post by Remarkable_Soil_2374 (Dec. 25, 2025), Dosage/Experience/Negatives; comments by Naven71, DiscreetAcct4 and PamelaF3211.Unverified oral capsules, calorie deficit and training. OP describes 2–3-week impressions and week-3 muted affect; Naven71 reports no effect after 30 days. Other commenters use different routes/blends. No isolated single-dose duration.
  • Looking for real-world experiences and data on 5-Amino-1MQ (opens in a new tab)Actual comments by Theappache10 (500 mcg–1.5 mg SC; limited energy, no claimed fat-burning benefit), Dull_Secretary_6734 (two weeks with Reta), and Letsgobeachfun (second dose with SS-31/Tirz/Glow).Unverified products, route and dose differences, co-use and short observation. OP asks a question rather than reporting completed use. Comments do not establish chloride superiority or a human half-life.

What people say 13

  • Waist / stuck cuts: Community logs describe modest midsection / clothing change when diet, steps, and (often) a GLP-1 or deficit are already in place — attribution confounded. forumanecdote
  • Appetite: Usually described as unchanged vs GLP-1s; standalone scale movement often milder and slower; animal work repeatedly notes weight/fat change without lower food intake. animalforum
  • Lean-mass narrative: “Fat off without muscle” is the marketing/community line; human DXA-quality proof is thin; animal work emphasizes WAT loss without lean collapse in short windows. animalforum
  • Energy / “things work better”: Subtle metabolic feel rather than stimulant buzz for many; a subset reports mild warmth/alertness or slight resting-HR uptick early; most noticeable in multi-agent recomp stacks (GLP-1 + MOTS-c + NAD precursor). forumanecdote
  • Visceral-fat story: Preclinical and clinic blogs emphasize visceral / white-adipose NNMT biology; human imaging endpoints not established. animalforum
  • Insulin / glucose (preclinical): Improved OGTT and insulin-sensitivity markers in longer DIO designs; community sometimes frames this as “metabolic flexibility” — not a diabetes drug claim. animalforum
  • Cholesterol (mice): Same short DIO window reported lower total plasma cholesterol vs vehicle. animal
  • Lipogenesis / cofactors (cells): Lower 1-MNA product, higher intracellular NAD+ and SAM in adipocyte models after NNMT block (e.g., 30 µM × 24 h in 3T3-L1 talk from the discovery series). lab
  • Selectivity talk: Scaffold described as selective for NNMT vs related SAM-dependent methyltransferases and NAD salvage enzymes in the discovery series; PAMPA / Caco-2 membrane-permeability work supported oral interest. trial
  • Diet synergy (mice): NNMTi + switch to lower-fat / reduced-calorie diet normalized adiposity/weight faster than diet switch alone (Dimet-Wiley / Sci Rep diet papers using 5A-1MQ; active API ~32 mg/kg SC in the 2022 Sci Rep design). animal
  • 28-day metabolic extension (mice): Babula et al. (Diabetes Obes Metab 2024) — once-daily 5A1MQ for 28 days dose-dependently limited body-weight and fat-mass gains, improved oral glucose tolerance and insulin sensitivity, suppressed hyperinsulinaemia, and improved liver weight/steatosis/inflammation markers in DIO mice without relying on food-intake cut as the main story; tissue distribution to adipose, muscle, and liver after SC dosing discussed. animal
  • Fat mass (DIO mice, short POC): Progressive body-weight loss vs saline over ~11 days SC NNMTi; epididymal fat-pad weight and adipocyte size down without food-intake change; ~34 mg/kg/day free-parent framing from 20 mg/kg/injection TID design (Neelakantan et al., Biochem Pharmacol 2018). animal
  • Aged muscle (mice): Dimet-Wiley et al., Sci Rep 2024 — 22-mo mice, once-daily SC 5A-1MQ 10 mg/kg × 8 weeks: NNMTi-treated sedentary cohort ~40% greater grip strength vs sedentary controls in the paper’s framing; exercise (PoWeR) alone ~20–40% depending on summary; NNMTi + exercise ~60% grip vs sedentary; sustained running-distance gains and lower intramuscular fat signals also discussed. animal

Doses people talk about 21

  • Dose-band chaos (critical): Public charts span roughly 150 mcg/day injectable up through 300–400 mg/day oral HED talk — multi-thousand-fold spread (YouTube/community “dosing problem” callouts often cite ~150 mcg to ~400 mg, ~2,500×). Treat any single “standard dose” as vendor/forum culture, not validated PK. forum
  • Oral common band (dominant): ~50–150 mg/day by mouth is the most repeated research-community range; 50 mg capsules are a frequent unit size. forum
  • Oral titration talk (copied chart): A frequently repeated chart describes ~50 mg once daily for 1–2 weeks, then ~100 mg/day (maintenance talk) or ~150 mg/day at the higher end; diminishing returns / more sides are sometimes claimed above ~150 mg. This is chart culture, not a validated progression. forum
  • Oral “75 mg” middle talk: Some forum guides call ~50–100 mg daily the common range with ~75 mg as the most-used single target after a 50 mg start. forum
  • Oral split (BID): 50 mg morning + 50 mg midday (or similar BID totaling ~100 mg) appears in discussion. Some writers cite multi-hour rodent t½ rather than weekly-peptide logic, but that does not establish the appropriate human interval or superiority over once-daily use. forum
  • Oral clinic-style TID: Functional-medicine / longevity writeups often cite ~50 mg one to three times per day (≈50–150 mg/day total), sometimes with meals for stomach comfort. forum
  • Oral conservative / low charts: ~5–25 mg/day oral appears in some stack guides (e.g., GLP-1 adjunct protocols that layer 5 mg → 10–25 mg); other writers call this under-dosed relative to HED from mice. forum
  • Injectable subQ — mg-band discussion: Informal guides describe ~2.5 mg/day as a tolerance phase and ~5 mg once daily (or 2.5 mg BID), often around 50 mg lyophilized vials; other forum guides say ~10–30 mg/day SC. These are conflicting chart amounts, not a progression; high-mg volume practicality is one reason writers contrast them with oral use. forum
  • Injectable subQ — mcg band (separate culture): Some clinic/forum 12-week tables describe ~150 mcg initially, ~300 mcg during weeks 2–4, ~450–500 mcg mid-block and up to ~600 mcg daily, sometimes split AM/PM. These are reported ladders, not instructions; the same name covers a very different magnitude from mg charts, which must not be mixed. forum
  • Route conversion: No human study equates oral mg to SC mcg/mg; rat oral F ~38% does not license a clean conversion formula; mouse oral F described as poor in some SC-preferring lab designs. trialanimalforum
  • Timing: Once-daily morning oral dominates; pre-cardio or fasted common; food optional for GI comfort; avoid doubling missed doses in informal protocols. forum
  • Named oral camps (2026): 50 mg start → ~100 mg/day is still the copied climb; ~75 mg is the “middle”; ~150 mg is the high-oral camp; a loud minority still argues 2 mg (usually inject) vs 150 mg oral as if they were the same chart. forum
  • Cardio-day split (n=1): Some oral logs run ~100 mg on cardio days and ~50 mg on other days (~70 mg average talk) — personal, not a protocol. anecdote
  • Sublingual empty-stomach camp: Morning 50 mg held sublingual then swallowed shows up in 2026 review-blog roundups; no human PK that it beats a capsule. forum
  • 2026 dose-spread threads: Public comments span ~2 mg injectable with “I’m flying” claims, 50 mg ×2 oral, and 25–50 mg/day injectable. These use different units/routes and are not interchangeable charts or proof of equivalent effects. forum
  • Oral high / exploratory: 100–300 mg+/day (and allometric chatter near ~400 mg/day human-equivalent from aggressive mouse scaling) — explicitly labeled experimental; not validated. forum
  • Purity / identity risk: Labels sometimes list “NNMT” (the enzyme) instead of the inhibitor; mg vs mcg vial errors and salt-form (iodide vs chloride) confusion appear in community QC talk. forum
  • Framing: Discussed research/community ranges only — not advice, not prescriptions; no published human trial dose. forumtrial
  • Animal — diet-synergy (not human): Dimet-Wiley 2022 used ~32 mg/kg active 5A-1MQ SC with low-fat diet switch (4 mg monochloride salt/mL saline at 10 mL/kg body weight in that methods writeup). animal
  • Animal — 28-day metabolic (not human): Babula et al. 2024 once-daily SC 5A1MQ × 28 days in DIO mice (dose-dependent PD; exact mg/kg ladder in paper — do not treat as human schedule). animal
  • Animal — Neelakantan DIO (not human): 20 mg/kg SC three times daily (~60 mg/kg/day nominal; ~34 mg/kg/day free parent in free-weight framing) for 11 days; escalation explored ~10–150 mg/kg/day total with ~60 mg/kg/day called well tolerated in n=2 pilot talk. animal

How it may feel 10

  • Days 1–7: Earlier community notes describe little acute “hit,” with occasional brief fatigue, GI noise, warmth/alertness, headache or slight resting-HR rise rather than a caffeine-like effect. In a month-long oral account, Remarkable_Soil_2374 reported no immediate stimulation; other commenters describe alertness or no benefit. Products, diet and stacks differ. forum
  • Weeks 1–2: Community logs track scale, waist tape, photos, sleep, stool and resting HR; appetite is often described as unchanged. Some oral charts use an initial ~50 mg period to discuss GI/sleep tolerance. This is self-log practice, not a validated assessment window. forum
  • Weeks 3–4: First “is anything happening?” window — slight clothing/waist change only if deficit, steps, and protein are already solid; animal fat-mass papers also sit in multi-week horizons. forumanimal
  • Weeks 4–8: Common window where recomp logs claim incremental midsection progress; still highly confounded by stacks and diet; informal “first visible change” talk often lands here if anywhere. forumanecdote
  • Weeks 6–12: Typical full community cycle length for judging a block; Dimet-Wiley muscle design used 8 weeks; Babula metabolic design used 28 days — neither is a human timeline. forumanimal
  • No change ~4–6 wk: Community troubleshooting: recheck true deficit, NEAT/steps, sleep, product identity/purity (COA), and which dose band was actually used (mg oral vs mcg inject chaos). forum
  • Evening dosing feel: Some informal reports link later-day dosing to sleep disruption / metabolic “activation”; morning dominates protocols. forum
  • Post-stop: No unique rebound lore unique to 5-Amino-1MQ; regain tracks calories and prior GLP-1/diet more than a classic rebound compound. anecdote
  • Flush / warmth: Minority oral logs mention warmth, extra cardio sweat, or a mild flush — not a classic nicotinic-acid face-red. NAD/niacin in the same stack confuses the story. forumanecdote
  • Muted mood (minority): A 2025–2026 month-log cluster mentions blunt/dull affect around week 3 at higher oral totals — diet-confounded, not a consensus AE. anecdote

Around the dose 6

  • Clock: Morning / earlier in the day in fat-loss charts. Night is uncommon. forum
  • Training: Paired with walking or lifting, not treated as a standalone fat burner. forum
  • Food: Oral; people still talk protein and not eating in a huge surplus “because NNMT.” forum
  • Fasted morning: Fat-loss charts often place capsules in the AM on an empty stomach; some oral logs instead mention food for GI comfort. Neither choice is a validated absorption or tolerance guarantee. forum
  • Cardio pairing: Extra sweat on zone-2/walk days is a common “is it doing anything” tell — still not a stimulant. forum
  • Methyl-support talk: TMG / methylated-B / MIC-blend neighbors show up because NNMT is a SAM consumer — stack logic, not a trial. forum

Cycles people discuss 8

  • Common oral block: 8–12 weeks on is the most repeated community cycle length. forum
  • Off period (wide): ~2–4 weeks off after an on-block is common; some guides prefer ~4–6 weeks off; other oral charts stretch off to ~4–8 weeks to “reset” NNMT baseline talk. forum
  • Short probe: 4–6 weeks before calling a null result, especially if stacked variables changed. forum
  • Clinic-style shorter: Some longevity/clinic writeups mention ~4–6 week 5-Amino-1MQ blocks with ongoing NAD support. forum
  • Continuous vs pulsed: Some stay on through a full cut; others pulse around diet stalls or late-phase GLP-1 plateaus. forum
  • Re-runs: Next recomp season restarts are common; multi-year continuous human safety data are not established. forum
  • Stack sequencing (community example): One blog pattern describes GLP-1 titration in weeks 1–4, MOTS-c + NMN/NR around week 5, then 5-Amino-1MQ around weeks 7–8. This is reported sequencing, not a studied combination or instructions to add agents. forum
  • Low-dose stack example: The same sequencing discussion contrasts a ~5 mg/day oral opening followed by 10–25 mg/day (low-chart camp) with 50→100–150 mg/day (dominant camp). These are conflicting chart traditions, not an instruction to choose or follow one. forum

Timing 9

  • Dosing logic in discussion: Once-daily and BID oral schedules circulate rather than weekly depot-peptide schedules. Some content creators cite ~7 h oral rat t½ to argue for BID, but animal half-life does not validate either human schedule. forum
  • Split-dose rationale: BID AM/midday splits are argued from short rodent t½, not proven human superiority. forum
  • Visible change lag: Body-comp change tracks deficit consistency and weeks of exposure more than a single plasma peak; mouse fat endpoints sat in ~11–28 day windows, muscle endpoints at 8 weeks. animalanecdote
  • Downstream biology: NNMT block → SAM/NAD shifts and gene-program remodeling in adipose can take days–weeks in models; subjective “feel” is often subtle. animalforum
  • Rat oral PK (Awosemo et al., JPBA 2021 LC-MS/MS): Terminal t½ ~6.90 ± 1.20 h oral; ~3.80 ± 1.10 h IV; oral bioavailability F% ≈ 38.4; substantial oral plasma exposure (mean Cmax ~2252 ng/mL oral in that design; mean AUC0–∞ ~14431 h·ng/mL oral vs ~3708 h·ng/mL IV in the reported groups). animal
  • Human PK: The checked rat study does not establish human capsule or SC kinetics; its abstract also does not specify the administered dose or salt form. A human estimate remains unresolved in this source review. trial
  • Species oral gap: Dimet-Wiley 2022 methods note poor oral bioavailability in mice (reason given for SC choice) that “does not occur in rats” — community oral-vs-inject arguments often ignore this species split. animal
  • Mouse half-life note: Separate MQ-scaffold / related-compound work has reported multi-hour mouse plasma half-lives (e.g., ~5.7 h in one related oral-gavage series) — compound- and study-specific. animal
  • Tissue distribution (animal): SC dosing associated with exposure in metabolically active tissues (adipose, muscle, liver) in 28-day PD framing — not human tissue PK. animal

More on what it is 7

  • Why people search it: Flagship non-GLP-1 fat-loss research compound with high talk volume: fat-cell-size / recomp narrative without the appetite crash of semaglutide-class drugs; heavily stacked late into GLP-1 plateaus. forum
  • Not: Not a GLP-1, not a stimulant thermogenic class drug, not pure NAD+ replacement, not an FDA-approved weight-loss drug, not the enzyme NNMT itself (vendors sometimes mislabel the enzyme as the ingredient), not interchangeable with other MQ-scaffold NNMTi analogs without study-specific data. trialforum
  • What it is: Small-molecule NNMT (nicotinamide N-methyltransferase) inhibitor — a charged 1-methylquinolinium salt (commonly iodide or chloride monosalts), not a peptide despite “amino” in the name and peptide-vendor placement. Research-only; not FDA-approved for weight loss as of mid-2026 status checks. trial
  • Mechanism (popular): NNMT methylates nicotinamide using SAM → makes 1-MNA and consumes methyl groups. Block NNMT → more NAD+ precursor flux + higher local SAM → adipocytes shift toward higher energy expenditure / less “storage” phenotype in models; SIRT1-adjacent talk often follows. labanimal
  • Foundational target rationale: Kraus et al. (Nature 2014) NNMT knockdown in WAT/liver protected against diet-induced obesity by raising energy expenditure — the enzyme-target story that later small-molecule NNMTis ride. animal
  • Key animal signal (obesity POC): DIO mice lost body weight and white-fat mass without eating less under short SC NNMTi (Neelakantan et al., Biochem Pharmacol 2018); later work pairs NNMTi with diet switch, extends to 28-day metabolic/liver endpoints, and tests aged-muscle strength. animal
  • Evidence honesty: Mouse/cell data and rat PK denser than human; as of mid-2026 community/regulatory summaries, no definitive human fat-loss RCT package is cited as published, and FDA has at least one compounding/503B-context warning letter naming the compound (GenoGenix, Jan 2026) — not an approval and not a safety clearance. trial

Stacks 10

  • GLP-1 / dual / triple agonists: Semaglutide, tirzepatide, retatrutide — framed as non-appetite metabolic / visceral adjunct once deficit exists; late-plateau midsection talk is common. forum
  • MOTS-c pair (flagship duo): Extremely common “mito + NNMT” fat-loss stack; MOTS-c AMPK/mito spend + 5-Amino-1MQ “stop the NAD precursor bleed” story. Example blog pairing: MOTS-c ~5–10 mg/week SC (2–3×/week) + 5-Amino-1MQ ~100 mg oral AM — not a trial. forum
  • NAD precursors: NMN or NR (~250–500 mg/day talk in stack blogs) co-run so more precursor is available when NNMT is blocked; some sequence NAD first, then MOTS-c, then 5-Amino-1MQ; others start NAD + MOTS-c together then add 5-Amino-1MQ. forum
  • Full metabolic stack example (blog, not trial): Retatrutide weekly + MOTS-c daily-ish + NMN/NR + 5-Amino-1MQ morning oral — track each lever separately. forum
  • MitoPrime-style blend talk: Commercial/community multi-agent NAD+/MOTS-c/5-Amino-1MQ blend naming; no combined human safety file — risk picture is pieced from parts. forum
  • Tesofensine oral pair: ~0.5 mg/day tesofensine (appetite DA/NE/5-HT) + ~100 mg/day 5-Amino-1MQ (metabolic) in some oral-only stack charts; stimulant-overlap caution when both raise alertness. forum
  • GH-axis / lipolytic neighbors: Tesamorelin (visceral GH axis), AOD-9604, Frag 176-191, ipamorelin/CJC-class in multi-agent cuts. forum
  • Other mito / recomp names: SS-31, SLU-PP-332 (exercise-mimetic small molecule; different target), urolithin A appear in anecdotal mega-stacks. forumanecdote
  • Baseline always credited: Progressive lifting + high protein + measured deficit/steps when “results looked good.” forum
  • Stack caution: Concurrent agents make before/after attribution impossible; no systematic interaction trials with GLP-1s, MOTS-c, tesofensine, or NAD precursors. forum

Access talk 1

  • [object Object]

Storage notes 2

  • No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
  • Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Watch for 19

  • Mild GI: Loose stool, stomach noise, or mild nausea first 1–2 weeks in some oral logs; sometimes mitigated by food. forum
  • Early fatigue: 1–3 days low energy in a subset of logs; causality unproven. forum
  • Headache: Occasional, typically mild and dose-related in community side-effect lists. forum
  • Warmth / mild stimulant-like feel / resting HR: Informal reports of warmth, alertness, or ~few-bpm resting-HR uptick early; if sustained/symptomatic, community stop-and-reassess talk. forum
  • Flush ≠ niacin flush: Warmth/flush reports get mixed with NAD or nicotinic acid. 5-Amino-1MQ is an NNMT inhibitor, not a flushing-niacin dose. forum
  • Sleep / evening dose: Metabolic activation / sleep disruption anecdotes favor morning-only schedules. forum
  • Injection local: Sting, itch, redness or soreness are described with subQ products; quinolinium chemistry is often blamed for sting. Abdomen, thigh and arm site-rotation talk also appears, but it does not establish product quality or a safe technique. forum
  • Methylation theory risk: NNMT is a major SAM consumer in adipose; systemic chronic inhibition could theoretically alter one-carbon / DNA / histone methylation balance elsewhere — discussed as theoretical, not a proven clinical table; methyl-donor-sensitive meds sometimes flagged in caution lists. forumtrial
  • Cancer biology complexity: NNMT is overexpressed in several cancers and discussed as biomarker/promoter in some contexts; net effect of long-term NNMT inhibition on cancer risk in humans is unknown (one in-vitro anti-proliferative signal in HeLa does not settle risk). Active malignancy is a common community caution flag. trialforum
  • Liver unknowns: Animal 28-day work reported improved steatosis markers at research doses, but that is not a human hepatology package; community sometimes suggests baseline ALT/AST curiosity — not a validated monitoring protocol. animalforum
  • Source quality: Mislabeling enzyme vs inhibitor, wrong dose unit (mg vs mcg), weak or fake COAs, salt-form ambiguity. forum
  • Interactions: No systematic clinical interaction data with prescription meds, concurrent GLP-1s, multi-peptide stacks, or high-dose methylated B-vitamin protocols. forum
  • Not “proven mild = proven safe”: Subjective tolerability on forums is not a substitute for controlled AE capture, labs, or long-term follow-up. forum
  • Access / RUO vs compounding: Oral capsules and lyophilized vials are research-chem; FDA compounding/503B warning-letter context (GenoGenix Jan 2026) is a status fight, not a green light. trialforum
  • Orange stain (inject): Some vial logs mention orange staining — handling nuisance, not an efficacy sign. anecdote
  • Human safety gap: Short rodent windows and cell work ≠ long-term human safety package; not FDA-approved for weight loss as of 2026 community status summaries. animaltrial
  • Compounding / regulatory note: FDA warning-letter context (e.g., GenoGenix Jan 2026) has named 5-Amino-1MQ in 503B bulks / compounding-eligibility discussion — a regulatory status finding, not an efficacy verdict. trial
  • Pregnancy / peds / unknowns: Not characterized; research-only framing. forum
  • Compare honestly to approved agents: Semaglutide/tirzepatide have large Phase 3 weight-loss packages; 5-Amino-1MQ does not — mechanism interest ≠ clinical equivalence. trial

Updated: 2026-09-01

Evidence mix Mostly community / anecdote tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.
↑ Back to top

All STUDresearch topics →